In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagement

Clinical Cancer Research

Volumn 18, Issue 22, 2012, Pages 6249-6259

  Benzaïd, Ismahène ^a,b,c   Mönkkönen, Hannu ^a,b,c   Bonnelye, Edith ^a,b,c   Mönkkönen, Jukka ^d   Clézardin, Philippe ^a,b,c  

^a INSERM   (France)

^b LabEx DEVweCAN   (France)

^c UNIVERSITÉ DE LYON   (France)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CELL SURFACE RECEPTOR; DOXORUBICIN; INTERCELLULAR ADHESION MOLECULE 1; ISOPENTENYL DIPHOSPHATE; PLACEBO; RISEDRONIC ACID; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; BREAST TUMOR; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL EXPANSION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; LYMPHOCYTOTOXICITY; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; ETIDRONIC ACID; FEMALE; GERANYLTRANSTRANSFERASE; HEMITERPENES; HUMANS; IMMUNOLOGIC FACTORS; INTERCELLULAR ADHESION MOLECULE-1; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED NOD; MICE, SCID; ORGANOPHOSPHORUS COMPOUNDS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES, CYTOTOXIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84869204667     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0918     Document Type: Article

References (22)

1. Coleman RE, Gnant M, Morgan G, Clezardin P. Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst 2012;104:1059-67.
2. Clézardin P. Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class. Bone 2011;48:71-9.
3. Stresing V, Fournier PG, Bellahcène A, Benzaïd I, Mönnkkönen H, Colombel M, et al. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase. Bone 2011;48:259-66.
4. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011;12:631-41.
5. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Stoeger H, Dubsky P, Jakesz R, et al. Long-term follow-up in ABCSG-12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine-receptor-positive early breast cancer [abstract]. Cancer Res 2011;71(Suppl.):S1 -2.
6. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011;365:1396-405.
7. Tanaka Y. Human γδ T cells and tumor immunotherapy. J Clin Exp Hematopathol 2006;46:11-23.
8. Kunzmann V, Bauer E, Wilhelm M. Gamma/delta T-cell stimulation by pamidronate. N Engl J Med 1999;340:737-8.
9. Roelofs AJ, Jauhiainen M, Mönkkönen H, Rogers MJ, Mönkkönen J, Thompson K. Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol 2009;144:245-50.
10. Fiore F, Castella B, Nuschak B, Bertieri R, Mariani S, Bruno B, et al. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. Blood 2007;110:921-7. (Pubitemid 47267430)
11. Vantourout P, Mookerjee-Basu J, Rolland C, Pont F, Martin H, Davrinche C, et al. Specific requirements for Vγ9Vδ2 T cell stimulation by a natural adenylated phosphoantigen. J Immunol 2009;183:3848-57.
12. Benzaïd I,Mönkkönen H, Stresing V, Bonnelye E, Green J,Mönkkönen J, et al. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res 2011;71:4562- 72.
13. Clézardin P, Massaia M. Nitrogen-containing bisphosphonates and cancer immunotherapy. Curr Pharm Des 2010;16:3007-14.
14. Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 2010;28:967-75.
15. Peyruchaud O, Winding B, Pecheur I, Serre CM, Delmas P, Clezardin P. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res 2001;16:2027-34. (Pubitemid 32995393)
16. Ottewell PD,Mönkkönen H, Jones M, Lefley DV, Coleman RE, Holen I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 2008;100:1167-78.
17. Mönkkönen H, Kuokkanen J, Holen I, Evans A, Lefley DV, Jauhiainen M, et al. Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth. Anticancer Drugs 2008;19:391-9.
18. Borgquist S, Djerbi S, Ponten F, Anagnostaki L, Goldman M, Gaber A, et al. HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors. Int J Cancer 2008;123:1146-53.
19. Stratowa C, Audette M. Transcriptional regulation of the human intercellular adhesion molecule-1 gene: a short overview. Immunobiology 1995;193:293-304.
20. Mattarollo SR, Kenna T, Nieda M, Nicol AJ. Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity. Cancer Immunol Immunother 2007;56:1285-97. (Pubitemid 46763941)
21. Santini D, Martini F, Fratto ME, Galluzzo S, Vincenzi B, Agrati C, et al. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother 2009;58:31-8.
22. Hamilton E, Clay TM, Blackwell KL. New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response. Cancer Invest 2011;29:533-41.